Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
April 09, 2021 09:00 ET | Sana Biotechnology, Inc
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
March 24, 2021 16:10 ET | Sana Biotechnology, Inc
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SEATTLE,...
Sana_Logo_RGB-72_Blue.png
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC)...
Sana_Logo_RGB-72_Blue.png
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 08, 2021 17:24 ET | Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its...
Sana_Logo_RGB-72_Blue.png
Sana Announces Upsized Pricing of Initial Public Offering
February 03, 2021 23:22 ET | Sana Biotechnology, Inc
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of...